Full Press Release Details
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP)
CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH MSD
SYDNEY, AUSTRALIA Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or
the Company ) has announced that it has entered into a clinical trial collaboration and supply agreement with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada), through a subsidiary, to
evaluate the combination of Immutep s lead immunotherapy product candidate eftilagimod alpha ( efti or IMP321 ) with MSD s anti-PD-1
therapy KEYTRUDA (pembrolizumab) in a new clinical trial that will evaluate the combination in several different solid tumours.
The planned Phase II clinical trial, referred to as TACTI-002 (Two ACTive Immunotherapies), will
evaluate the safety and efficacy of this novel immunotherapy combination in patients with non-small cell lung cancer ( NSCLC ), head and neck cancer, or ovarian cancer. The TACTI-002 clinical trial will be a Phase II, Simon two-stage, non-comparative, open-label,
single-arm, multicentre clinical study. Up to 120 patients across the three indications are planned to be treated in medical centres in Europe and the United States with the trial expected to commence in the
second half of 2018.
We are extremely pleased to be collaborating with MSD, one of the world s leading immuno-oncology companies said
Marc Voigt, CEO of Immutep. This clinical trial will evaluate a novel combination of two complementary immuno-oncology treatments in three cancer indications simultaneously, which could lead to more rapid drug development subject to successful
outcomes. The data generated thus far from our ongoing TACTI-mel clinical trial has supported our hypothesis that there is a compelling therapeutic synergy in administering efti in combination with another immuno-oncology treatment. This new Phase
II clinical trial significantly builds on the momentum we are delivering in the evaluation of efti in cancer, with two Phase I clinical trials and now two Phase II clinical trials in our program for 2018.
The trial combines two immuno-oncology treatments with complementary mechanisms of action, analogous to releasing the brakes and pushing the accelerator of
the body s immune system at two different positions in the cancer immunity cycle. Immutep s efti is a first-in-class antigen presenting cell ( APC )
activator which stimulates cancer-fighting T cells, while KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of the body s immune system to help
detect and fight tumor cells.
is a globally active biotechnology company that is a leader in the development of immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative
treatment options to market for patients and to maximise value to shareholders.
Immutep s current lead product is eftilagimod alpha
( efti or IMP321 ), a soluble LAG-3Ig fusion protein based on the LAG-3 immune control mechanism. This mechanism plays a vital role in the
regulation of the T cell immune response. Eftilagimod alpha, alone or in combination with other therapeutics, has completed early Phase II trials as an APC activator boosting T cell responses for cancer chemo-immunotherapy. Additional LAG-3 products, including antibodies, for immune response modulation in autoimmunity and cancer are being developed by Immutep s large pharmaceutical partners.
Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the U.S.
KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of
Merck & Co., Inc., Kenilworth, NJ, USA.
For further information please visit www.immutep.com or contact:
Jay Campbell, Vice President of Business
Development and Investor Relations, Immutep Limited
+1 (917) 860-9404; jay.campbell@immutep.com
Australian Investors/Media:
Matthew Gregorowski,
+61 2 8234 0105; mgregorowski@citadelmagnus.com